The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

Lars Rebien Sorensen

UPDATED: U.S. payer pressures force Novo Nordisk to cut loose 1,000 staffers

UPDATED: Novo Nordisk chief Lars Rebien Sorensen to step down early as pricing pressures mount